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use determined that early revisions/reoperations were more frequent in HR than 
in THA (range 3.1-13.1 vs. 1.9-7.5 per 1000 person years, respectively). 
CONCLUSIONS: This systematic review provides clinicians and health policy 
makers with information on adverse events based on device type and market 
status. Rates of adverse events vary by device type, making it challenging to 
conclude which device is more effective. Findings highlight the importance of 
differentiating market status and standardizing exposure time by 1000 person 
years to facilitate comparisons between studies.  
 
PMS5  
ADVERSE EVENTS ASSOCIATED WITH COLCHICINE DRUG INTERACTIONS: 
ANALYSIS OF THE PUBLIC VERSION OF THE FDA ADVERSE EVENT REPORTING 
SYSTEM  
Almalki Z1, Guo JJ1, Kelton CM2, Wigle PR1 
1University of Cincinnati College of Pharmacy, Cincinnati, OH, USA, 2University of Cincinnati 
College of Business, Cincinnati, OH, USA  
OBJECTIVES: Colchicine was originally used, and continues to be used, to treat 
rheumatic diseases. It is used most frequently for the treatment of gout but is 
also used to treat familial Mediterranean fever, pericarditis, and Behcet’s disease. 
However, because of its pharmacokinetics, colchicine can interact dangerously 
with other drugs. The objective of the study was to analyze the association 
between drug-drug interactions involving colchicine and major adverse events 
as reported in the U.S. FDA Adverse Event Reporting System (FAERS). METHODS: 
All major adverse events (including death, initial or prolonged hospitalization, 
and persistent or significant disability) related to colchicine between 2004 and 
2011 were retrieved from FAERS. Then, events evidently caused by interactions 
with drugs (such as atazanavir, clarithromycin, indinavir, itraconazole, 
ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, 
cyclosporine, and ranolazine) were distinguished from events evidently caused 
by colchicine as the primary suspect drug. Major adverse event rates were 
calculated. RESULTS: Between 2004 and 2011, a total of 2655 adverse event 
reports involving colchicine interactions with other drugs were found in the 
FAERS database, of which 718 reported a death (implying a fatality ratio of 
27.0%), 762 reported a hospitalization (giving a 28.7% hospitalization rate), 78 
referred to life-threatening events, and 56 reported disability. Pancytopenia, 
renal failure, vomiting, drug toxicity, and diarrhea were the most common 
reported events. There were 4,717 reports involving colchicine as the primary 
suspect drug, of which 527 reported a death (fatality ratio of 11.2%). A 
statistically significant (p<0.001) difference between the two fatality ratios was 
found. CONCLUSIONS: When combined with certain other drugs, evidence 
suggests that colchicine may be associated with a relatively high death rate, 
especially if not dosed appropriately. In light of the current data, physicians 
should be keenly aware of all potentially fatal drug-drug interactions and follow 
therapeutic guidelines on using colchicine.  
 
PMS6  
INTENSIVE CARE UNIT ADMISSION AMONG TRUMA PATIENTS AT A LARGE 
TRAUMA CENTER IN SAUDI ARABIA  
Alghnam S1, Alkelya M2, Albedah K3 
1University of Wisconsin, Madison, WI, USA, 2King Abdullah International Medical Research 
Center (KAIMRC); King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, 
Saudi Arabia, 3King Abdulaziz Medical City, Riyadh, Saudi Arabia  
OBJECTIVES: Despite risk of mortality, traffic-related injuries place a significant 
financial burden on the health sector, especially due to costs like intensive  
care unit (ICU) admission and prolonged hospital stays. The aim of the study is 
to investigate risk factors of admission to the ICU among injured-patients 
admitted to a large urban trauma center in Saudi Arabia. METHODS: This 
analysis was performed using a dataset from King Abdulaziz Medical City  
in Riyadh, Saudi Arabia. 7,859 patients met the inclusion criteria during the 
study period (injured due to falls or traffic crashes and admitted to the hospital 
between years 2001-2010). Backward-stepwise logistic regression, with admission 
to the ICU as the outcome, was performed. Variables with p-values<0.1  
were included in the final model. Model discrimination was evaluated using the 
Area Under the Curve (AUC). RESULTS: A total of 1833 injured individuals (23.3%) 
were admitted into the ICU during the study period. They had longer hospital 
stay and were more likely to be males, sustain head injuries, and to undergo 
surgery. Multivariate analysis identified injury severity score, Glasgow coma 
scale, injury mechanism, head injury, and direct transfer to surgery as 
significant predictors of admission to the ICU. The results indicate that 
compared to falls, all traffic-related injuries were significantly more likely lead to 
ICU admission (occupants OR=2.5, [95% CI: 2.0-3.0]; pedestrians OR=2.7, [95% CI: 
2.1-3.4]; motorcycle OR=1.7, [95% CI: 1.1-2.7]) adjusting for other covariates. The 
model showed excellent discrimination ability as shown by [AUC=0.90]. 
CONCLUSIONS: This model can facilitates the triage process of injured patients 
by assisting in identify those at higher risk of ICU admission. Unlike the U.S, 
emergency health care services are free in Saudi Arabia and costs are mostly 
absorbed by the admitting hospital. Therefore, public health interventions are 
needed to alleviate the burden traffic injuries place on health care settings and 
improve population health.  
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ORAL GLUCOCORTICOID USE IN RITUXIMAB-TREATED RHEUMATOID 
ARTHRITIS PATIENTS WITH PRIOR EXPOSURE TO ANTI-TUMOR NECROSIS 
FACTOR-ALPHA THERAPY  
Johnston SS1, Kamath T2, Shi N3, Fowler R1, Chu BC4, Reiss W2 
1Truven Health Analytics, Washington, DC, USA, 2Genentech, South San Francisco, CA, USA, 
3Truven Health Analytics, Cambridge, MA, USA, 4Truven Health Analytics, Santa Barbara, CA, USA  
OBJECTIVES: Long-term use of oral glucocorticoid (OGC) therapy may be 
associated with adverse effects; thus, OGC-sparing approaches to treatment of 
rheumatoid arthritis (RA) may benefit patients. This study examined OGC use in 
rituximab-treated RA patients with prior exposure to anti-tumor necrosis factor-
alpha (anti-TNF) therapy. METHODS: Administrative claims-based retrospective 
study. Study patients met the following criteria: initiated rituximab between 
March 1, 2006-March 31, 2011 (initiation date=index) after exposure to anti-TNF 
therapy, aged ≥18 years, had a medical claim with a diagnosis code for RA (ICD-9-
CM 714.0x) between January 1, 2004-March 31, 2011, continuously enrolled for 12 
months before and ≥90 days after index, had no medical claims with diagnosis 
codes for non-RA indications of biologic disease modifying antirheumatic drugs 
(BDMARDs) within 12 months before index. Using rituximab infusion dates and 
the recommended administration frequency schedule, rituximab exposure 
periods were constructed. Exposure periods commenced upon index and 
terminated at the first occurrence of switch to a different BDMARD, 90-day gap in 
rituximab treatment, loss to follow-up, or follow-up of 36 months. Outcomes 
were any OGC use and mean daily OGC dose expressed in prednisone equivalent 
and averaged among all patients, measured throughout the exposure period in 
sequential 90-day intervals. Multivariable generalized estimating equation 
models tested for statistically significant changes in OGC use over time. 
RESULTS: Study included 1,763 rituximab exposure periods (1,718 unique 
patients); mean age 54.9 years, 81.5% female, 54.0% with OGC use within 30 days 
before index. Between the first and last 90-day intervals, the probability of OGC 
use and the mean daily OGC dose decreased significantly: from 0.56 to 0.36 
(p<0.001) and from 3.5mg/day to 2.7mg/day (primarily driven by OGC 
discontinuation) (p<0.001), respectively. Sensitivity analyses subset to exposure 
periods lasting a full 36 months yielded similar results. CONCLUSIONS: 
Statistically significant decreases in OGC use were observed in rituximab-treated 
RA patients with prior exposure to anti-TNF therapy.  
 
PMS8  
ASSESSMENT OF THE INCIDENCE OF FLARES FOR GOUTY ARTHRITIS PATIENTS 
WITHIN THE SCOTT & WHITE HEALTH CARE SYSTEM  
Adeyemi A1, Rascati KL1, Cheng LI1, Prasla K2 
1The University of Texas at Austin, Austin, TX, USA, 2Scott & White Health Plan, Temple,  
TX, USA  
OBJECTIVES: To identify features that characterize difficult-to-treat gout patients 
based on the number of flares experienced within a 12-month period. METHODS: 
A retrospective database analysis was conducted using electronic medical 
records, laboratory reports and demographic data files. Eligible patients were 
above 18 years, with at least one diagnosis of gout and/or a gout-related 
medication between January 1, 2005 and December 31, 2010. Patients with at 
least one serum uric acid value and at least one flare were followed for 12 
months from the date the first flare was reported. Eligible patients who had no 
flares within the study period were also included. RESULTS: A total of 266 
patients met study criteria, the mean age (±SD) was 61.2 years (±15.7), the 
majority were males (n=180; 67.7%), the mean annual flare rate was 1.80 (±1.11), 
and the mean serum uric acid value was 7.24mg/dl (±2.07). Based on three 
categories of flare rates, 110 patients (41.4%) had no flares, 107 patients (40.2%) 
had one or two flares, and 49 patients (18.4%) had at least 3 flares. ANOVA tests 
detected significant differences in mean serum uric acid values by flare rate 
(F=18.34; df=2; p<0.0001). Kruskal-Wallis results indicated a significant 
relationship between serum uric acid l ˂evel categories (  6.0 mg/dl, ≥6.0-  ˂9.0 mg/dl 
and ≥9.0 mg/dl) and flare rates; X2=32.26; df=2; p<0.0001. There was no significant 
difference in flare rate by age (F=0.31; df=2; p=0.7355). Although Wilcoxon results 
showed a significant relationship between serum uric acid level categories and 
gender (X2=7.10; df=1; p=0.0077), no significant relationship between flare rates 
and gender (X2=1.67; df=1; p=0.1959) was observed. CONCLUSIONS: More 
information is required to be able to identify and characterize difficult-to-treat 
gout patients.  
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COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH 
ANKYLOSING SPONDYLITIS (AS) RECEIVING THEIR FIRST BIOLOGIC IN UK, 
GERMANY, FRANCE, ITALY AND SPAIN (5EU)  
Narayanan S1, Lu Y2, Hutchings R2, Baskett A2 
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK  
OBJECTIVES: To compare the disease status and outcomes of patients with AS 
receiving their first biologic in 5EU. METHODS: A multi-country multi-center 
medical chart-review study of AS patients was conducted among physicians 
(rheumatologists:97%) in hospitals and private practices to collect de-identified 
data on patients who were recently treated with a biologic as part of usual care. 
Physicians were screened for duration of practice (3-30 yrs) and patient volume 
(incl. >5AS biologic patients/month) and recruited from a large panel to be 
geographically representative in each country. Eligible patient charts (>3) were 
randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Physicians abstracted patient 
diagnosis, treatment patterns/dynamics and patient symptomatology/disease 
status/outcomes. RESULTS: In 1Q2012, 1095 eligible AS patient charts were 
abstracted; 935 (85%) patients were on their first biologic (mean-age:42.6yrs, 
female:20%). Geographic distribution of patients were – UK:20%, Germany:18%, 
France/Italy:21%, Spain:19%. Time-to-1st biologic from diagnosis (range:28month 
(Italy)-59month (France)) and time-on-current biologic (range:24month 
(UK/Germany/Italy)-27month (France)) differed within 5EU. Among the top-3 
reasons for biologic treatment initiation, ‘mechanism of action’ & ‘improve 
signs/symptoms’ were observed across 5EU, whereas ‘positive personal 
experience’ (UK/Germany/France) and ‘preservation of structural damage’ 
(Italy/Spain) were also observed. Key lab measures documented were: ESR 
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(range:15.1mm/h (France)-21.0mm/h (Italy)) and CRP (range:5.6mg/dl (Spain)-
12.5mg/dl (UK)). Current disease severity per physician-judgment 
(mild:moderate:severe) in 5EU were: UK-68%:22%:10%, Germany-57%:39%:5%, 
France-46%:47%:7%, Italy-64%:34%:2%, Spain-69%:27%:4%. Among patients with 
available data, current HAQ (range: 0.7(France)-1.5(Germany)), BASDAI 
(range:3.0(Spain)-3.4(UK)), 100mmVAS (range:19.0(France)-31.4(UK)) and Swollen 
Joint Count (range:0.5(France)-(3.7(UK)) differed within 5EU. Among patients with 
available data, response to current biologic per ASAS criteria were 
(%ASAS20:%ASAS40:ASAS5/6:%ASAS partial-remission): UK-12%:6%:0%:4%, 
Germany-20%:9%:9%:11%, France-13%:7%:7%:11%, Italy-30%:17%:13%:18%, Spain-
19%:13%:5%:13%. CONCLUSIONS: Among AS patients receiving their first 
biologic, disease severity differed within 5EU, with patients in the UK with 
relatively higher burden and poorer treatment response. Impact of specific 
biologic treatments on the observed patterns warrants further scrutiny.  
 
PMS10  
COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH 
PSORIATIC ARTHRITIS (PSA) RECEIVING THEIR FIRST BIOLOGIC IN UK, 
GERMANY, FRANCE, ITALY AND SPAIN (5EU)  
Narayanan S1, Lu Y2, Hutchings R2, Baskett A2 
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK  
OBJECTIVES: To compare the disease status and outcomes of patients with PsA 
receiving their first biologic in 5EU. METHODS: A multi-country multi-center 
medical chart-review study of PsA patients was conducted among physicians 
(rheumatologists:97%) in hospitals and private practices to collect de-identified 
data on patients who were recently treated with a biologic as part of usual care. 
Physicians were screened for duration of practice (3-30 yrs) and patient volume 
(incl. >5PsA biologic patients/month) and recruited from a large panel to be 
geographically representative in each country. Eligible patient charts (>3) were 
randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Physicians abstracted patient 
diagnosis, treatment patterns/dynamics and patient symptomatology/disease 
status/outcomes. RESULTS: In 1Q2012, 1099 eligible PsA patient charts were 
abstracted; 916 (83%) patients were on their first biologic (mean-age:48.1yrs, 
female:46%). Geographic distribution of patients were – UK:20%, Germany:18%, 
France:22%, Italy:21%, Spain:19%. Time-to-1st biologic from diagnosis 
(range:31month (Italy)-50month (UK)) and time-on-current biologic 
(range:19month (Italy)-24month (France)) differed within 5EU. The top-4 reasons 
for biologic treatment initiation across 5EU were ‘mechanism of action’, ‘improve 
signs/symptoms’, ‘preservation of structural damage’ and ‘positive personal 
experience’. Key lab measures documented were: ESR (range:18.6mm/h (France)-
25.2mm/h (Italy)) and CRP (range:6.3mg/dl (Spain)-14.5mg/dl (UK)). Current 
disease severity per physician-judgment (mild:moderate:severe) in 5EU were: 
UK-61%:25%:13%, Germany-57%:37%:6%, France-44%:46%:11%, Italy-56%:41%:2%, 
Spain-64%:33%:3%. Among patients with available data, current HAQ (range: 
0.7(Spain)-1.5(Germany)), BASDAI (range:2.7(Spain)-3.9(UK)), 100mmVAS 
(range:23.9(Spain)-31.4(UK)) and Swollen Joint Count (range:1.2(Spain)-(3.7(UK)) 
differed within 5EU. Among patients with available data, response to current 
biologic per ASAS criteria were (%ASAS20:%ASAS40:ASAS5/6:%ASAS partial-
remission): UK-8%:8%:0%:4%, Germany-18%:7%:9%:12%, France-11%:6%:6%:10%, 
Italy-29%:16%:12%:15%, Spain-13%:14%:9%:9%. CONCLUSIONS: Among PsA 
patients receiving their first biologic, disease severity and outcomes differed 
within 5EU, with patients in the UK with relatively higher burden and poorer 
treatment response. Impact of specific biologic treatments on the observed 
patterns warrants further scrutiny.  
 
PMS11  
META-ANALYSIS FOR EFFICACY OF ETANERCEPT FOR TREATMENT OF 
PSORIATIC ARTHRITIS  
Aggarwal S, Topaloglu H, Messenger M 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: Psoriatic arthritis (PA) is an inflammatory disease affecting joints 
and connective tissues. The anti-tumor necrosis factor (TNF) biologics are 
increasingly being used in patients who have failed traditional disease-
modifying antirheumatic drugs. Etanercept has shown efficacy in treatment of 
PA. The objective of this study was to conduct meta-analysis and present total 
evidence for etanercept in treatment of PA. METHODS: For this meta-analysis we 
included randomized controlled trials (RCTs)evaluating etanercept for the 
treatment of PS. RCTs studying adult populations with active and progressive PA 
with an inadequate response to previous DMARD therapy were eligible. Trials 
conducted among PA populations with prior experience with anti-TNF agents, 
including an inadequate response, were excluded. A systematic literature search 
for Etanercept trials was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar, and Cochrane. Data was collected for the study size, 
interventions, year, and the three outcomes HAQ, PASI and PsARC. For meta-
analysis, random effects and fixed effects models were used to obtain 
cumulative statistics. RESULTS: Two RCTs with a total of 131 patients were 
identified. The pooled response rates for Etanercept for PsARC were 75% (95% CI 
60%-90%), for HAQ were 59% (95% CI 46%-72%), and for PASI were 24% (95% CI 
13%-34%). The pooled response rates for placebo for PsARC were 30% (95% CI 
26%-35%), for HAQ were 5% (95% CI 1%-9%), and for PASI were 3% (95% CI 0%-7%). 
For PsARC the cumulative relative risk with Etanercept versus placebo was 0.40 
(95% CI 33%-48%). For HAQ, the cumulative relative risk with Etanercept versus 
placebo was 0.08 (95% CI 5%-12%). For PASI, the cumulative relative risk with 
Etanercept versus placebo was 0.14 (95% CI 8%-20%). CONCLUSIONS: Meta-
analysis shows Etanercept offers patients with psoriatic arthritis an effective 
therapeutic option for control of their disease.  
PMS12  
STRUCTURING CRITERIA IN MULTI-CRITERIA DECISION MODELS FOR 
BENEFIT/RISK ASSESSMENT OF BIOLOGICS IN JUVENILE ARTHRITIS  
Satiti M1, IJzerman MJ1, Boere-Boonekamp M1, Bridges JFP2 
1University of Twente, Enschede, The Netherlands, 2Johns Hopkins Bloomberg School of Public 
Health, Baltimore, MD, USA  
OBJECTIVES: Multi-criteria decision analysis (MCDA) is a technique which is 
proposed for quantitative benefit/risk assessment. MCDA structures benefits and 
risks in a decision or value tree, either by forming hierarchical clusters of 
benefits and risks separately or by placing both benefits and risks on the same 
level allowing direct comparison of all benefits and risks (non-hierarchical). The 
objective of this study was to compare two approaches for structuring decision 
trees and to evaluate the rank-order of three TNF– inhibitors for Methotrexate 
type of Juvenile Idiopathic Arthritis (JIA). METHODS: The alternatives selected for 
evaluation were Etanercept, Infliximab and Adalimumab. Six criteria were 
identified for evaluation, including improvement in pain, improvement in social 
function, Methotrexate (MTX) discontinuation, administration reaction, serious 
infection and cancer. The criteria were structured both non–hierarchically and 
hierarchically. Two different questionnaires were developed and randomized to 
42 physicians in three hospitals. Weight elicitation was performed using the 
Analytic Hierarchy Process. RESULTS: In hierarchical structures, the criterion 
weights were more steep and the range between most and least important 
criterion was larger than in non-hierarchical structures. Risks were considered 
more important (aggregated wrisk=0.35) in an non-hierarchical structure than in 
an hierarchical structure (wrisk=0.20). Applying the performance weights for three 
TNF-a inhibitors showed that there is a different rank-order of drugs being 
considered. The weights elicited from non–hierarchical questionnaire showed 
Etanercept to be most preferred. Yet, Adalimumab was most preferred if a 
hierarchical structure was used. The non–hierarchical questionnaire could be 
transformed to a hierarchical structure after which a similar rank-order of drugs 
was found as in the hierarchical structure. CONCLUSIONS: The rank order of the 
alternatives indeed changes when the criteria were structured differently 
regardless where the criteria weights were obtained from similar or different 
group of participants. Policy implications need to be explored.  
 
PMS13  
ASSESSING THE GEOGRAPHIC AND DEMOGRAPHIC VARIATION ASSOCIATED 
WITH PSORIATIC ARTHRITIS PREVALENCE IN THE VETERAN POPULATION IN 
THE UNITED STATES  
Wang L1, Huang A1, Baser O2 
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research/The University of Michigan, 
Ann Arbor, MI, USA  
OBJECTIVES: To study the relationship between psoriatic arthritis (PsA) 
prevalence and geographic variation and demographic characteristics in the U.S. 
veteran population. METHODS: Using the Veterans Health Administration (VHA) 
Medical SAS Datasets from October 1, 2005 to May 31, 2012, a retrospective 
database analysis was performed. All U.S. veteran beneficiaries diagnosed with 
PsA were identified using International Classification of Disease 9th Revision 
Clinical Modification (ICD-9-CM) diagnosis code 696.0. All patients with medical 
benefit enrollment in 2011 were included in the study. Descriptive statistics were 
calculated as means±standard deviation (SD) and percentages to measure age, 
race and other related factors in the sample. RESULTS: A total of 22,102 veterans 
were diagnosed with PsA during 2011. The state of Vermont had the highest 
prevalence rate (0.29%), followed by New Hampshire (0.23%), and Maine (0.23%). 
All other states were observed with prevalence rates lower than 0.2%. 
Washington D.C. had only three cases of the disease, which translated into 0.02% 
of prevalence. Patients age 55-64 were most likely to be diagnosed with PsA 
(0.15%). Prevalence was lower by 0.05% for patients age 35-54 and 65+ (0.10%). 
Younger patients were less likely to be diagnosed with the disease (<0.05%). PsA 
diagnoses also varied by race: Non-Hispanic White (0.14%), Hispanic (0.12%), 
Non-Hispanic Black (0.03%), and other races (0.08%). CONCLUSIONS: PsA was 
unevenly distributed across the United States when measured by age group and 
race. Geographic variation was also related to disease occurrence. These factors 
should be taken into consideration for further studies.  
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ANNUAL MORTALITY IN A LARGE PREVALENCE-BASED SAMPLE OF UNITED 
STATES RHEUMATOID ARTHRITIS PATIENTS  
Palmer LA, Farr A, Johnston SS 
Truven Health Analytics, Washington, DC, USA  
OBJECTIVES: Studies estimating mortality rates in United States rheumatoid 
arthritis (RA) patients have largely been based upon registry or single-center 
populations numbering in the hundreds or few thousands of RA patients, which 
limits the generalizability of their findings. The objective of this study was to 
describe annual mortality in a large prevalence-based sample of U.S. RA patients. 
METHODS: This was a retrospective study based on mortality data obtained from 
the Social Security Administration (SSA) linked to approximately 15 million 
individuals present in the Truven Health MarketScan® Commercial and Medicare 
Supplemental administrative claims databases. The SSA data currently include 
information on whether individuals were living or had died (including date of 
death) as of October 31, 2012. To maximize generalizability, this study used a 
prevalence-based sampling technique whereby RA patients representing a broad 
spectrum of disease durations and severity were selected. To that end, patients 
aged 18+ years were selected for study if they were continuously enrolled in 
insurance benefits throughout calendar year 2010 and during this time period 
had at ≥1 medical claim with an ICD-9-CM code for RA (714.0x). Claims that may 
have represented efforts to ‘rule out’ the presence of RA were excluded from 
consideration. The study outcome was age/sex-specific mortality rates in 2011. 
